Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 13/20 | 0.62 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22518550 | 0.85 | APLNR (0.60) | APLNR | |
| SCHEMBL22518498 | 0.84 | APLNR (0.59) | APLNR | |
| SCHEMBL22518537 | 0.81 | APLNR (0.67) | APLNR | |
| SCHEMBL20207367 | 0.80 | APLNR (0.62) | APLNR | |
| SCHEMBL18246804 | 0.79 | APLNR (0.68) | APLNR | |
| SCHEMBL22518495 | 0.76 | APLNR (0.55) | APLNR | |
| SCHEMBL18246411 | 0.76 | APLNR (1.00) | APLNRTSHR | |
| SCHEMBL20190081 | 0.76 | APLNR (0.64) | APLNR | |
| SCHEMBL20189941 | 0.76 | APLNR (1.00) | APLNRTSHR | |
| SCHEMBL22518510 | 0.76 | APLNR (0.57) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3541805-B1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3541805-B1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3541805-A1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018097945-A1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AGTR1, AGTR2, TBXA2R | APLNR 13/4885RECQL 4327/4885TSHR 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.